OBJECTIVE: To develop treatment recommendations for children with juvenile idiopathic arthritis manifesting as non-systemic polyarthritis, sacroiliitis, or enthesitis. METHODS: The Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions were developed and refined by members of the guideline development teams. A systematic review was conducted to compile evidence for the benefits and harms associated with treatments for these conditions. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of evidence. A group consensus process was conducted among the Voting Panel to generate the final recommendations and grade their strength. A Parent and Patient Panel used a similar consensus approach to provide patient/caregiver preferences for key questions. RESULTS: Thirty-nine recommendations were developed (8 strong and 31 conditional). The quality of supporting evidence was very low or low for 90% of the recommendations. Recommendations are provided for the use of nonsteroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, biologics, and intraarticular and oral glucocorticoids. Recommendations for the use of physical and occupational therapy are also provided. Specific recommendations for polyarthritis address general medication use, initial and subsequent treatment, and adjunctive therapies. Good disease control, with therapeutic escalation to achieve low disease activity, was recommended. The sacroiliitis and enthesitis recommendations primarily address initial therapy and adjunctive therapies. CONCLUSION: This guideline provides direction for clinicians, caregivers, and patients making treatment decisions. Clinicians, caregivers, and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
OBJECTIVE: To develop treatment recommendations for children with juvenile idiopathic arthritis manifesting as non-systemic polyarthritis, sacroiliitis, or enthesitis. METHODS: The Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions were developed and refined by members of the guideline development teams. A systematic review was conducted to compile evidence for the benefits and harms associated with treatments for these conditions. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of evidence. A group consensus process was conducted among the Voting Panel to generate the final recommendations and grade their strength. A Parent and Patient Panel used a similar consensus approach to provide patient/caregiver preferences for key questions. RESULTS: Thirty-nine recommendations were developed (8 strong and 31 conditional). The quality of supporting evidence was very low or low for 90% of the recommendations. Recommendations are provided for the use of nonsteroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, biologics, and intraarticular and oral glucocorticoids. Recommendations for the use of physical and occupational therapy are also provided. Specific recommendations for polyarthritis address general medication use, initial and subsequent treatment, and adjunctive therapies. Good disease control, with therapeutic escalation to achieve low disease activity, was recommended. The sacroiliitis and enthesitis recommendations primarily address initial therapy and adjunctive therapies. CONCLUSION: This guideline provides direction for clinicians, caregivers, and patients making treatment decisions. Clinicians, caregivers, and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
Authors: Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: Gordon H Guyatt; Andrew D Oxman; Regina Kunz; David Atkins; Jan Brozek; Gunn Vist; Philip Alderson; Paul Glasziou; Yngve Falck-Ytter; Holger J Schünemann Journal: J Clin Epidemiol Date: 2010-12-30 Impact factor: 6.437
Authors: Jeff Andrews; Gordon Guyatt; Andrew D Oxman; Phil Alderson; Philipp Dahm; Yngve Falck-Ytter; Mona Nasser; Joerg Meerpohl; Piet N Post; Regina Kunz; Jan Brozek; Gunn Vist; David Rind; Elie A Akl; Holger J Schünemann Journal: J Clin Epidemiol Date: 2013-01-09 Impact factor: 6.437
Authors: Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; J Chavez-Corrales; Christian Huemer; Alan Kivitz; Francisco J Blanco; Ivan Foeldvari; Michael Hofer; Gerd Horneff; Hans-Iko Huppertz; Chantal Job-Deslandre; Anna Loy; Kirsten Minden; Marilynn Punaro; Alejandro Flores Nunez; Leonard H Sigal; Alan J Block; Marleen Nys; Alberto Martini; Edward H Giannini Journal: Arthritis Rheum Date: 2010-06
Authors: E H Giannini; E J Brewer; N Kuzmina; A Shaikov; A Maximov; I Vorontsov; C W Fink; A J Newman; J T Cassidy; L S Zemel Journal: N Engl J Med Date: 1992-04-16 Impact factor: 91.245
Authors: Laura C Coates; Arthur Kavanaugh; Philip J Mease; Enrique R Soriano; Maria Laura Acosta-Felquer; April W Armstrong; Wilson Bautista-Molano; Wolf-Henning Boehncke; Willemina Campbell; Alberto Cauli; Luis R Espinoza; Oliver FitzGerald; Dafna D Gladman; Alice Gottlieb; Philip S Helliwell; M Elaine Husni; Thorvardur J Love; Ennio Lubrano; Neil McHugh; Peter Nash; Alexis Ogdie; Ana-Maria Orbai; Andrew Parkinson; Denis O'Sullivan; Cheryl F Rosen; Sergio Schwartzman; Evan L Siegel; Sergio Toloza; William Tuong; Christopher T Ritchlin Journal: Arthritis Rheumatol Date: 2016-03-23 Impact factor: 10.995
Authors: Daniel J Lovell; Nicolino Ruperto; Richard Mouy; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhaes; J Chavez-Corrales; Christian Huemer; Alan Kivitz; Francisco J Blanco; Ivan Foeldvari; Michael Hofer; Hans-Iko Huppertz; Chantal Job Deslandre; Kirsten Minden; Marilynn Punaro; Alan J Block; Edward H Giannini; Alberto Martini Journal: Arthritis Rheumatol Date: 2015-10 Impact factor: 10.995
Authors: Vinita M Alexander; Jillian Ashley-Martin; Joan K Riley; Amber R Cooper; Valerie S Ratts; Emily S Jungheim Journal: Reprod Biomed Online Date: 2021-03-31 Impact factor: 4.567
Authors: Pamela F Weiss; Robert C Fuhlbrigge; Emily von Scheven; Daniel J Lovell; Robert A Colbert; Hermine I Brunner Journal: Arthritis Care Res (Hoboken) Date: 2022-04-15 Impact factor: 5.178
Authors: Lianne Kearsley-Fleet; Eleanor Heaf; Rebecca Davies; Eileen Baildam; Michael W Beresford; Helen E Foster; Taunton R Southwood; Wendy Thomson; Kimme L Hyrich Journal: Lancet Rheumatol Date: 2020-03-09